Comparative cost-effectiveness analysis of the subacromial spacer for irreparable and massive rotator cuff tears

• DOI: 10.1007/s00264-018-4065-x
• Publication Date: 2018-07-31T06:59:55Z
• Authors: Alessandro Castagna; Raffaele Garofalo; Eran Maman; Alisha C. Gray; Elizabeth A. Brooks
• Keywords: Original Paper; Cost-Benefit Analysis; Joint Prosthesis; Conservative Treatment; Arthroplasty; Rotator Cuff Injuries; 3. Good health; Arthroscopy; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Arthroplasty, Replacement, Shoulder; Absorbable Implants; Humans

There is ongoing debate regarding the optimal surgical treatment of irreparable rotator cuff tears (IRCT). This study aimed to assess within the Italian health care system the cost-effectiveness of subacromial spacer as a treatment modality for patients with IRCT.An expected-value decision analysis was created comparing costs and outcomes of patients undergoing arthroscopic subacromial spacer implantation, rotator cuff repair (RCR), total shoulder arthroplasty, and conservative treatment for IRCTs. A broad literature search provided input data to extrapolate and inform treatment success and failure rates, costs, and health utility states for these outcomes. The primary outcome assessed was an incremental cost-effectiveness ratio (ICER) of subacromial spacer implantation versus shoulder arthroplasty, RCR, and conservative treatment.Subacromial spacer is favorable over both arthroscopic partial repair and shoulder arthroplasty since it costs less than both options and increases effectiveness by 0.06 and 0.10 quality-adjusted life years (QALYs), respectively. While conservative treatment is the least costly management strategy, subacromial spacer results in a gain of 0.05 QALYs for the additional cost of 522 €, resulting in an ICER of 10,440 €/QALY gain, which is below the standard willingness to pay ratio of $50,000 USD. Strategies with an ICER of less than 50,000 USD are considered to be cost-effective.Based on the available evidence and reasonably conservative assumptions, subacromial spacer is likely to provide a safe, effective, and cost-effective option for patients with massive IRCTs. Furthermore, this cost-effectiveness analysis may ultimately serve as a guide for development of health care system and insurer policy as well as clinical practice.